Results 21 to 30 of about 56,538 (251)

Prevalence of sexual disorders in relapsing-remitting multiple sclerosis patients depending on various risk factors [PDF]

Romanian Journal of Medical Practice
Objective. Multiple sclerosis is a perilous, disabling, physically as well as mentally, demyelinating disease of the central nervous system. This work aims to evaluate prevalence of sexual dysfunctions and their correspondence with non- and disease ...
Tetiana Odintsova, Oksana Kopchak
doaj   +1 more source

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [PDF]

, 2003
OBJECTIVE: To evaluate the cost effectiveness of four disease modifying treatments (interferon betas and glatiramer acetate) for relapsing remitting and secondary progressive multiple sclerosis in the United Kingdom. DESIGN: Modelling cost effectiveness.
Abrams, K., Chilcott, J., Claxton, K., Cooper, N.J., McCabe, C., O'Hagan, A., Tappenden, P.   +6 more
core   +2 more sources

Current management of relapsing‐remitting multiple sclerosis [PDF]

Internal Medicine Journal, 2014
AbstractMultiple sclerosis was without effective disease‐modifying therapy for many years. The introduction of the injectable therapies (interferon and glatiramer acetate) some 20 years ago was considered a major advance. Recent years have heralded a revolution in treatment options with the introduction of intravenous natalizumab and, even more ...
L, Sedal, I B, Wilson, E A, McDonald
openaire   +2 more sources

Emerging immunopharmacological targets in multiple sclerosis. [PDF]

, 2015
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the
Abdolmohamad Rostami, Abrams, Abrams, Achiron, Adelman, Allen, Bachmann, Bai, Bai, Baker, Balcer, Bar-Or, Bar-Or, Bar-Or, Bar-Or, Ben-Nun, Biasi, Bielekova, Bielekova, Bielekova, Bielekova, Bielekova, Bitar, Bluestone, Bogoljub Ciric, Bour-Jordan, Bourdette, Bourquin, Brambilla, Brocke, Burman, Burns, Burrows, Chaudhuri, Chitnis, Coles, Constantinescu, Constantinescu, Correale, Correale, Cox, Cragg, Crowe, Darlington, Darlington, Disanto, Duddy, Emery, Espinoza-Delgado, Faria, Faria, Farjam, Feinstein, Fissolo, Fletcher, Freedman, Garren, Garren, Garren, Garren, Giovannoni, Giovannoni, Girvin, Girvin, Goodin, Gosselin, Goverman, Goverman, Guang-Xian Zhang, Hale, Hartmann, Hauser, Havrdova, Hawker, He, Hedegaard, Higgins, Hill-Cawthorne, Hilliard, Hilliard, Ho, Hoffmann, Hofman, Jankovic, Jennum, Kappos, Kappos, Karussis, Karussis, Kearney, Kerbrat, Le Page, Li, Liblau, Lider, Lider, Lindsey, Lindsey, Lisak, Liu, Lobell, Lobell, Lohse, Lund, Lyons, Marrie, Marta, Martin, Mease, Medaer, Mestecky, Mikulkova, Miller, Milo, Mirshafiey, Mojtaba Farjam, Moreau, Mowat, Nicoletti, Nightingale, O'Brien, Offner, Offner, Oh, Oksenberg, Pender, Pettitt, Phillips, Phillips, Podojil, Poli, Pozzilli, Pryce, Quintana, Racioppi, Rasouli, Robinson, Rose, Rose, Rostami, Sandrini, Schaub, Sclerosis, Selmaj, Selmaj, Sinha, Smith, Spuler, Stuve, Taoufik, Tsunoda, Turley, Turley, Turner, van Boxel-Dezaire, van den Hoogen, Van der Walt, van Oosten, van Oosten, van Oosten, Vandenbark, Vandenbark, Viglietta, Viglietta, Vollmer, Walczak, Waldmann, Wang, Weber, Wefer, Weiner, Weiner, Weissert, Willis, Wucherpfennig, Wynn, Xing, Yadav, Zang, Zhang, Zhang, Zhang, Zhang   +182 more
core   +2 more sources

Vitamin D and Disease Severity in Multiple Sclerosis-Baseline Data From the Randomized Controlled Trial (EVIDIMS) [PDF]

, 2020
Objective: To investigate the associations between hypovitaminosis D and disease activity in a cohort of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) patients.
Bellmann-Strobl, Judith, Brandt, Alexander Ulrich, Bäcker-Koduah, Priscilla, Dörr, Jan, Paul, Friedemann, Scheel, Michael, Wernecke, Klaus-Dieter, Wuerfel, Jens   +7 more
core   +2 more sources

Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis

Arquivos de Neuro-Psiquiatria, 2011
Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests ...
Dóra-Neide Rodrigues, Renata Alves Paes, Claudia Cristina Ferreira Vasconcelos, Jesus Landeira-Fernandez, Maria Papais Alvarenga   +4 more
doaj   +1 more source

Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study.

PLoS ONE, 2023
Although the causes of multiple sclerosis are largely unknown, genetic and environmental components play an important role. Geographic distribution, varying with latitude, reflects both genetic and environmental influences.
Gil Harari, Michael Gurevich, Mark Dolev, Rina Zilkha Falb, Anat Achiron   +4 more
doaj   +1 more source

▼Dimethyl fumarate for relapsing-remitting multiple sclerosis [PDF]

Drug and Therapeutics Bulletin, 2014
For many years the only drugs licensed for the treatment of multiple sclerosis (MS) were administered by injection (interferon beta, glatiramer and ▼natalizumab). Recently, three oral drugs have become available. We have previously reviewed the use of ▼fingolimod for highly active relapsing-remitting MS1 and ▼teriflunomide for the management of ...
Martyn J, Burke, Joanna, Richardson, Elisabeth, George, Amanda I, Adler   +3 more
openaire   +4 more sources

Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: The Escala study [PDF]

, 2015
Objective: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-β.
García-Bujalance, Laura, Meca-Lallana, José, Sánchez-de la Rosa, Rainel   +2 more
core   +1 more source

Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study [PDF]

, 2004
Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C ...
Achiti, J., Arbizu, T., Arnulf, I., Aubertin, P., Bamborschke, P., Belliard, S., Berger, E., Blanc, S., Brassat, D., Brochet, B., Cahagne, V., Casado, A., Cesaro, P., Chan, A., Clanet, M., Confavreux, C., Dalecky, A., Damier, P., de Keyser, Jacques, de Marco, A., Defer, G., Degos, F., Dengler, R., Dose, A., Edan, G., Engles, A., Fernandez, O., Flachenecker, A., Gayou, A., Gelderblom, H., Grunwald, F., Grupe, A., Hartung, H.P., Heesen, C., Heidenreich, F., Heinzlef, O., Hohlfeld, R., Kappos, L., Kassim, N., Koehler, A., Koerner, A., Kristoferitsch, W., Kunze, K., Kyriallis, K., Lau, G., Lecanuet, P., Lindert, A., Liu, A., Lubetzki, C., Luenemann, J., Lyon-Caen, O., Magnier, C., Martin, A, Martinez-Yelamos, A., Matzke, A., Maurer, A., Mekies, C., Menck, A., Montalban, X., Moulin, A., Nolden, A., Nos, A., Pantzaris, A., Papacostas, S., Pelletier, J., Petereit, H., Pez, D., Piette, A., Riche, G., Rieckmann, P., Romero, F., Rouanet, M., Rouant, F., Roullet, E., Rumbach, L., Sailer, 27449, Schaeffer, S., Schlederer, A., Schrieber, A., Seeldrayers, P., Senard, A., Stankoff, B., Steiner, A., Stingle, A., Storch-Hagenlocher, A., Storch-Hagenlocher, B., Suchet, L., Tamayo, J.A., Tamman, D., Thalamas, C., Vermersch, P., Vogt-Schaden, A., Vuilleman, C., Weilbach, A., Weiler, C., Windhagen, A., Zorgdrager, A., Zschenderlein, R., Zwanniken, G.   +98 more
core   +1 more source